IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY

被引：0

作者：

Cramer, P.

Chanan-Khan, A. ^{[1
]}

Demirkan, F. ^{[2
]}

Fraser, G. ^{[3
]}

Santucci Silva, R. ^{[4
]}

Pylypenko, H. ^{[5
]}

Grosicki, S. ^{[6
]}

Janssens, A. ^{[7
]}

Pristupa, A. ^{[8
]}

Mayer, J. ^{[9
]}

Dilhuydy, M. S. ^{[10
]}

Loscertales, J. ^{[11
]}

Bartlett, N. L. ^{[12
]}

Avigdor, A. ^{[13
,14
]}

Rule, S. ^{[15
]}

Sun, S. ^{[16
]}

Mahler, M. ^{[16
]}

Salman, M. ^{[16
]}

Howes, A. ^{[17
]}

Hallek, M. ^{[18
,19
]}

机构：

[1] Mayo Clin, IL-52621 Jacksonville, FL USA

[2] Dokuz Eylul Univ, Juravinski Canc Ctr, IL-69978 Izmir, Turkey

[3] McMaster Univ, Hemomed Oncol & Hematol, Hamilton PL6 8DH, ON, Canada

[4] IEP SAO LUCAS, Dept Hematol, Sao Paulo, Brazil

[5] Cherkassy Reg Oncol Ctr, Fac Publ Hlth, Dept Canc Prevent, Cherkassy, Ukraine

[6] Silesian Med Univ, D-50931 Katowice, Poland

[7] Univ Ziekenhuizen Leuven, D-50931 Leuven, Belgium

[8] Reg Clin Hosp, Dept Internal Med Hematol & Oncol, Ryazan, Russia

[9] Univ Hosp Brno, Brno, Czech Republic

[10] Hop Haut Leveque, Hematol Dept, IIS IP, Pessac, France

[11] Hosp Univ La Princesa, Sch Med, Siteman Canc Ctr, Madrid, Spain

[12] Washington Univ, Div Hematol & Bone Marrow Transplantat, St Louis, MO USA

[13] Chaim Sheba Med Ctr, Sackler Sch Med, Tel Hashomer, Israel

[14] Tel Aviv Univ, Dept Haematol, Tel Aviv, Israel

[15] Derriford Hosp, Plymouth, Devon, England

[16] Janssen Res & Dev LLC, Raritan, NJ USA

[17] Janssen Res & Dev, Dept Internal Med 1, High Wycombe, Bucks, England

[18] Univ Cologne, Ctr Integrated Oncol, Cologne, Germany

[19] Univ Cologne, Cologne, Germany

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB218

引用

页码：55 / 56

页数：2

共 50 条

[31] Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study
Hallek, Michael
Fraser, Graeme
Cramer, Paula
Demirkan, Fatih
Silva, Rodrigo Santucci
Grosicki, Sebastian
Janssens, Ann
Pristupa, Aleksander
Mayer, Jiri
Dilhuydy, Marie Sarah
Loscertales, Javier
Bartlett, Nancy
Avigdor, Abraham
Rule, Simon
Sun, Steven
Mahler, Michelle
Phelps, Charles
Salman, Mariya
Howes, Angela
Chanan-Khan, Asher
LEUKEMIA & LYMPHOMA, 2017, 58 : 192 - 194
[32] Patterns of Lymphocytosis in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Idelalisib
Brown, Jennifer R.
Cheson, Bruce D.
Furman, Richard R.
Ghia, Paolo
Hallek, Michael
Hillmen, Peter
O'Brien, Susan M.
Sharman, Jeff P.
Dubowy, Ronald L.
Velasco, Barbara
Waldapfel, Christopher C.
Zelenetz, Andrew D.
BLOOD, 2015, 126 (23)
[33] Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice
Finnes, Heidi D.
Chaffee, Kari G.
Call, Timothy G.
Ding, Wei
Kenderian, Saad S.
Bowen, Deborah A.
Conte, Michael
McCullough, Kristen B.
Merten, Julianna A.
Bartoo, Gabriel T.
Smith, Matthew D.
Leis, Jose
Chanan-Khan, Asher
Schwager, Susan M.
Slager, Susan L.
Kay, Neil E.
Shanafelt, Tait D.
Parikh, Sameer A.
LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1376 - 1383
[34] A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Zelenetz, A.
Lamanna, N.
Kipps, T.
Coutre, S.
O'Brien, S.
Graves, J.
Ye, W.
Dubowy, R.
Flinn, I.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 97 - 97
[35] A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Zelenetz, Andrew D.
Lamanna, Nicole
Kipps, Thomas J.
Coutre, Steven E.
O'Brien, Susan
Aiello, Maria
Cho, Yoonjin
Dubowy, Ronald L.
Flinn, Ian W.
BLOOD, 2014, 124 (21)
[36] A phase 2 study of idelalisib monotherapy in previously untreated patients ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Zelenetz, Andrew
Lamanna, Nicole
Kipps, Thomas
Coutre, Steven
O'Brien, Susan
Graves, Jaime
Ye, Wei
Dubowy, Ronald
Flinn, Ian
LEUKEMIA & LYMPHOMA, 2015, 56 : 97 - 98
[37] A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
Eradat, Herbert Aaron
Coutre, Steven E.
Barrientos, Jacqueline Claudia
Rai, Kanti Roop
Farber, Charles Michael
Hillmen, Peter
Sharman, Jeff Porter
Ghia, Paolo
Coiffier, Bertrand
Walewski, Jan Andrzej
Berneman, Zwi N.
O'Brien, Susan Mary
Brown, Jennifer R.
Peterman, Sissy
Dansey, Roger D.
Jahn, Thomas Michael
Cramer, Paula
Hallek, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[38] Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Tam, Constantine S.
Siddiqi, Tanya
Allan, John N.
Kipps, Thomas J.
Flinn, Ian W.
Kuss, Bryone J.
Opat, Stephen
Barr, Paul M.
Tedeschi, Alessandra
Jacobs, Ryan
Badoux, Xavier C.
Ghia, Paolo
Sukbuntherng, Juthamas
Salem, Ahmed Hamed
Russell, Kristin
Eckert, Karl
Zhou, Cathy
Ninomoto, Joi
James, Danelle F.
Wierda, William G.
BLOOD, 2019, 134
[39] Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
Moreno, Carol
Greil, Richard
Demirkan, Fatih
Tedeschi, Alessandra
Anz, Bertrand
Larratt, Loree
Simkovic, Martin
Samoilova, Olga
Novak, Jan
Ben-Yehuda, Dina
Strugov, Vladimir
Gill, Devinder
Gribben, John G.
Hsu, Emily
Zhou, Cathy
Clow, Fong
James, Danelle F.
Styles, Lori
Flinn, Ian W.
BLOOD, 2018, 132
[40] Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
Huang, Xiaojun
Qiu, Lugui
Jin, Jie
Zhou, Daobin
Chen, Xiequn
Hou, Ming
Hu, Jianda
Hu, Yu
Ke, Xiaoyan
Li, Junmin
Liang, Yingmin
Liu, Ting
Lv, Yue
Ren, Hanyun
Sun, Aining
Wang, Jianmin
Zhao, Chunting
Salman, Mariya
Sun, Steven
Howes, Angela
Wang, Jingzhao
Wu, Peng
Li, Jianyong
CANCER MEDICINE, 2018, 7 (04): : 1043 - 1055

← 1 2 3 4 5 →